Home Tags Genetics
Jeffrey Epstein had a ‘Frankenstein’-like plan to analyze human DNA in the US Virgin Islands, and it reportedly pulled in $200 million
Epstein pursued an outlandish scheme to launch a 'DNA mining' startup. Scientists said his plan made no sense.
Bank of America Merrill Lynch's "underperform" rating marks the first time since March a Wall Street firm has recommended selling.
From suicide prevention to genetic testing, there’s a widening disconnect between Silicon Valley health tech and outside experts who see red fla...
"There's almost this implicit assumption that they play by a different set of rules," a Harvard psychiatrist and tech consultant said.
We’ll be eating the first Crispr’d foods within 5 years, according to a geneticist who helped invent the blockbuster gene-editing tool
A UC Berkeley geneticist who helped invent the gene-editing tool Crispr told Business Insider its most profound impacts will be on agriculture.
A Silicon Valley startup just launched a DNA-based health test that could be a big competitor to 23andMe
A new genetic test looks at your risk of diseases like cancer and high cholesterol. Unlike 23andMe's test, it includes genetic counseling and full sequencing.
Jo Cameron said that she feels very minimal pain, anxiety, and depression and in a new paper, experts think they have figured out why that is.
The CEO of Silicon Valley’s favorite meal-replacement startup shares why he thinks the tide is shifting on genetic engineering
"The pendulum is swinging in favor of the science," Soylent CEO Bryan Crowley told Business Insider.
A new study suggests some women may have an active gene that leads to a faster breakdown of contraceptive hormones in pills and implants.
Certain genetic mutations may mean some people could have no limit to how much they can drink, according to a study of drunk mice.
Swiss drug giant Roche reportedly readies to buy the biotech behind the first FDA-approved gene therapy and the priciest medicine in the US
Roche could pay $5 billion for biotech company Spark Therapeutics. The pharma giant likely wants to expand its presence in hemophilia, a lucrative market.